Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRACAnalysis CDx as a companion diagnostic tool for Lynparza

13 Aug 2015

Abstract excerpt

Lynparza and its companion diagnostic test, BRACAnalysis were approved by the US FDA in December 2014 for recurrent ovarian cancer in women with a germline BRCA mutation. Women with a deleterious BRCA mutation are predisposed to ovarian cancer due to deficient homologous recombination repair. Inhibition of the PARP enzyme forces use of an alternate error-prone pathway for repair; PARP trapping is another...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26292709
DOI: 10.1586/14737159.2015.1078238

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRACAnalysis CDx as a companion diagnostic tool for LynparzaPMID 26292709Read ↗

Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis and TreatmentSemantic proximity Read ↗

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical PerspectivesSemantic proximity Read ↗

Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancerSemantic proximity Read ↗

Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer.Semantic proximity Read ↗

A profile on the FoundationFocus CDxBRCA tests.Semantic proximity Read ↗

Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literatureSemantic proximity Read ↗

Evaluation of Rucaparib and Companion Diagnostics in the PARP Inhibitor Landscape for Recurrent Ovarian Cancer TherapySemantic proximity Read ↗

HRD-One: CLINICAL VALIDATION AND PERFORMANCE ASSESSMENT. Comparison between Myriad’s myChoice®, SOPHiA GENETICS® SOPHiA Homologous Recombination Solution and AmoyDx® HRD Focus PanelSemantic proximity Read ↗

A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer DiagnosisSemantic proximity Read ↗

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical ConsiderationsSemantic proximity Read ↗

A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies.Semantic proximity Read ↗

Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnosticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.